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Abstract
Background: In order to review the epidemiologic evidence concerning previous lung diseases as risk factors for lung
cancer, a meta-analysis and systematic review was conducted.
Methods: Relevant studies were identified through MEDLINE searches. Using random effects models, summary effects of
specific previous conditions were evaluated separately and combined. Stratified analyses were conducted based on
smoking status, gender, control sources and continent.
Results: A previous history of COPD, chronic bronchitis or emphysema conferred relative risks (RR) of 2.22 (95% confidence
interval (CI): 1.66, 2.97) (from 16 studies), 1.52 (95% CI: 1.25, 1.84) (from 23 studies) and 2.04 (95% CI: 1.72, 2.41) (from 20
studies), respectively, and for all these diseases combined 1.80 (95% CI: 1.60, 2.11) (from 39 studies). The RR of lung cancer
for subjects with a previous history of pneumonia was 1.43 (95% CI: 1.22–1.68) (from 22 studies) and for subjects with a
previous history of tuberculosis was 1.76 (95% CI=1.49, 2.08), (from 30 studies). Effects were attenuated when restricting
analysis to never smokers only for COPD/emphysema/chronic bronchitis (RR=1.22, 0.97–1.53), however remained
significant for pneumonia 1.36 (95% CI: 1.10, 1.69) (from 8 studies) and tuberculosis 1.90 (95% CI: 1.45, 2.50) (from 11
studies).
Conclusions: Previous lung diseases are associated with an increased risk of lung cancer with the evidence among never
smokers supporting a direct relationship between previous lung diseases and lung cancer.
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Introduction
Lung Cancer is the most common cancer and the overall
leading cause of cancer-related mortality worldwide leading to
greater than a million deaths annually [1]. Recent evidence
suggests that inflammatory processes may play a central role in
carcinogenesis [2,3,4,5]. Previous lung diseases/conditions such as
chronic obstructive pulmonary disease (COPD) (emphysema and
chronic bronchitis), pneumonia and tuberculosis are major sources
of inflammation in lung tissue [6,7]. These conditions may act as
intermediates or catalysts in the development of lung neoplasms
and appear to be related to lung cancer development through
common etiologies and/or exposures [8]. The combined preva-
lence of previous lung conditions is high across populations and as
such they may be important sources of increased lung cancer risk
[9,10], particularly among never smokers.
The associations between COPD, (emphysema and/or chronic
bronchitis), pneumonia and tuberculosis and lung cancer have
been investigated previously, however, the evidence is inconclusive
due to inconsistent findings and small sample sizes - 65% of the
studies identified having less than 500 cases. We therefore
conducted a systematic review of the scientific literature in order
to conduct a meta-analysis of the associations between COPD,
emphysema, chronic bronchitis, pneumonia, tuberculosis and lung
cancer risk. The main issue in investigating previous lung diseases
and lung cancer risk is the possible confounding by smoking. In
this analysis, we focused on the direct effects of disease by
addressing the potential role of confounding from smoking in these
associations with lung cancer. This was assessed through study
eligibility and subgroup analysis in studies of never smokers.
Previous Lung Diseases
COPD is characterized by airflow obstruction in the lungs and
the related symptoms that impede the normal expiratory volume
of the lungs [11]. COPD most commonly refers to patients with
emphysema (the enlargement and destruction of the alveoli) and/
or chronic bronchitis (chronic inflammation and scarring of
bronchi) [12]. The condition has been defined in several ways, and
the differences in definitions and diagnosis affect the estimates of
the burden of the disease. The most common definitions involve
either airflow limitation (American Thoracic Society) or reduced
maximum expiratory flow (European Respiratory Society) which is
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Chronic Obstructive Lung Disease (GOLD) defines the disease
in stages of clinical severity based on forced expiratory volume
(FEV1 & FEV1/FVC) from post-bronchodilator spirometry [13].
The disease affects a large proportion of adults with prevalence
estimates varying from 4.3% to 5.9% in the US adult population
[14]. COPD has been associated with active tobacco smoking
(attributable risk estimates in the range of 45% (UK) and 50%
(US) among adults) [15,16], however, chronic bronchitis and less
frequently emphysema are also observed among lifetime non-
smokers (chronic bronchitis prevalence among nonsmokers varies
across populations 6.3–12.1% [17,18]). The incidence rate of
COPD among never smokers increases with age to approximately
10–12% by age 75 in males and to approximately 20% in by age
75 in females [19].
Pneumonia is an infection of the lungs and respiratory tract
most often caused by viruses, bacteria and other organisms.
Infection is quite common among adults and pneumonia incidence
is highest in the elderly and very young where immune systems are
compromised. The highest hospital discharge rate for pneumonia
per age group in the US was among those 65 and over at 221.3 per
10,000 [20]. The most common method of clinical diagnosis for
pneumonia employs the use of serum antibody determination,
particularly microimmunofluorescence [21].
Tuberculosis, another type of infection affecting the lungs is
caused by mycobacteria, predominantly Mycobacterium tubercu-
losis. The incidence of tuberculosis among industrialized countries
is approximately 23 cases per 100,000, much lower than the 100–
230 cases per 100,000 in other developing countries [22,23].
Although mortality due to tuberculosis is low in industrialized
countries, inflammation and ensuing lung remodeling has been
hypothesized to lead to lung cancer development [24,25,26].
Materials and Methods
Literature Review
We conducted a literature search using the MEDLINE database
(US National Library of Medicine) from January 1960 to August
2010 to obtain a comprehensive list of publications containing risk
estimates describing the association between lung cancer and
previous lung diseases including COPD, emphysema, chronic
bronchitis, pneumonia and tuberculosis. Two independent
reviewers conducted literatures searches and data abstraction.
We utilized the Medical Subject Headings ‘‘COPD’’ or ‘‘chronic
obstructive pulmonary disease’’ or ‘‘emphysema’’ or ‘‘chronic
bronchitis’’ or ‘‘pneumonia’’ or ‘‘tuberculosis’’ or ‘‘respiratory
tract diseases’’ or ‘‘lung diseases’’ and ‘‘lung neoplasm’’ or the text
word terms ‘‘previous lung disease’’ and ‘‘lung cancer’’. Titles and
abstract were reviewed for article relevance. In the detailed review
of relevant papers effect estimates were extracted including odds
ratios, relative risks (RR), hazard ratios (HR) and their
corresponding 95% confidence intervals from all included studies.
When the same population was examined in multiple publications,
we included only the estimate with the largest number of cases
reported. Where studies reported estimates for both the total
population and among only never smokers within that population
[17,28,29,30], the total population estimates were used to combine
estimates in all cases except subgroup analysis among never
smokers.
Studies were excluded if (i) estimates were not adjusted for
smoking status [31,32,33,34,35,36,37,38] given the strong poten-
tial for confounding by smoking; (ii) effect estimates for individual
conditions were not reported in the paper [39,40]; (iii) estimates
were based on symptoms only rather than the actual diagnoses
[41,42]; (iv) no diagnostic cut point was provided that could be
used to combine the studies (e.g., only estimates for percentiles of
lung function scores compared with the reference group of highest
lung function were provided) [43,44].
Given that COPD is a term generally used to describe
emphysema and chronic bronchitis, the inflammation and
enlargement of air sacs in the lungs, resulting in reduced or
limited airflow [12], the meta-analysis was based on estimates
reported for these three conditions/classifications combined as
well as reported separately (i.e., COPD, emphysema, chronic
bronchitis).
Data collection and diagnostic criteria varied across studies and
conditions. For COPD, most of the studies collected data based on
self-reported condition from questionnaires (i.e. ‘‘Did a doctor ever
diagnosis you with…?’’), while four several used 1-second forced
expiratory volume over forced vital capacity (FEV1/FVC) or the
percent of the predicted forced expiratory volume in 1 second (%
FEV1) [45,46,47,48,49]. Emphysema was defined in most studies
by self-reported condition, however, a small number of studies
employed either quantitative CT scan [45,50] or radiographic
evidence [51]. Pneumonia was defined by self-reported condition
or by microimmunofluorescence [52,53,54,55] examining for the
levels of IgA antibodies for the C. pneumoniae bacteria. Tuberculosis
was assessed by self-reported history or X-ray [56].
Statistical Methods
Random effects models were employed for all meta-analyses
[57]. For all previous lung diseases and all subgroups, the potential
for publication bias was evaluated by funnel plots and the methods
described by Egger [58] et al and Begg et al [59]. Heterogeneity
was evaluated using Cochrane’s Q-statistic test [60] and the I
2
statistic [61]. Where there was evidence of heterogeneity across
studies, the source of heterogeneity was evaluated by meta-
regression (Continent, smoking status, diagnostic method, gender,
date study completed, study design and control type used as
predictors) and by stratified analysis on smoking status, type of
controls, method of diagnosis, study period and gender. If the
heterogeneity could not be accounted for by the different
characteristics, an influence analysis was conducted to evaluate
the source of heterogeneity from single studies by a Galbraith plot
and evaluating changes in Q statistics upon study removal.
Analyses were also conducted based on ‘‘never smokers only’’ to
eliminate possible confounding by smoking. Studies are classified
as never smokers where the population consisted exclusively of
never smokers by design. A latency analysis was conducted based
on study eligibility where studies that excluded persons with a lung
disease diagnosis .2, .10 and .20 years before diagnosis were
examined across groups. Analyses were conducted using Com-
prehensive Meta-Analysis Software Version 2 (CMA, NJ), and
STATA software version 10 (STATA, College Station TX).
Results
In total 39 studies were identified that examined the effects of
COPD, chronic bronchitis and/or emphysema with estimates
adjusted for smoking (Table S1). Specifically, there were 16 studies
with estimates of COPD on lung cancer risk; 20 with emphysema
and 23 with chronic bronchitis (59 total estimates based on 39
studies). Among the 39 studies, there were 18 population-based
and 12 hospital-based case-control studies, 1 mixed case-control
study and 8 cohort studies. Out of the 39 studies, 13 studies
presented estimates among never smokers only, which reported 23
estimates for various conditions. For pneumonia we identified 22
studies in total, including 10 studies with never smokers only. For
Previous Lung Disease and Lung Cancer Risk
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with populations of never smokers.
COPD/emphysema/chronic bronchitis
Thirty-nine studies examined the relationship between COPD
and/or chronic bronchitis and/or emphysema and lung cancer
while adjusting for smoking (Table S1). Nineteen of the studies
were conducted in North America [17,29,30,39,45,46,48,51,62,
63,64,65,66,67,68,69,70,71,72], 12 were conducted in Asia
[73,74,75,76,77,78,79,80,81,82,83,84], 6 in Europe [28,47,50,
85,86,87] and 1 in Africa [88]. The combined relative risk (RR) of
lung cancer based on all 59 effect estimates was 1.83 (95%
confidence interval (CI): 1.60, 2.11). Figure 1 displays a forest plot
of the association with estimates separated by each condition
(chronic bronchitis, emphysema, COPD as reported in the
publication) as well as all conditions combined. It is noteworthy
that in examining only those studies that employed a physiological
diagnosis of COPD from FEV testing or radiographic evidence of
emphysema, the RR was elevated compared to self-reported
diagnoses (RR=2.64, 95% CI: 2.01, 3.47). Among never smokers
we did not observe a significant association of all COPD,
emphysema and chronic bronchitis estimates combined
(RR=1.22, 95% CI: 0.97, 1.53), however, when the outlying
study was removed from the analysis, the effect was 1.29, 95% CI:
1.02–1.63.
In terms of disease-specific estimates, the overall RRs for of
COPD, emphysema and chronic bronchitis were 2.22 (95% CI:
1.66, 2.97),2.04(95% CI: 1.72, 2.41) and 1.52(95% CI: 1.25, 1.84),
respectively. When restricted to never smokers, associations were
not significant for emphysema based on 8 studies (RR=1.50, 95%
CI: 0.96, 2.36), or for chronic bronchitis based on 12 studies
(RR=1.18, 95% CI: 0.88, 1.58). Since passive smoking may
confound the association between COPD and lung cancer,
sensitivity analyses focused on the four studies that adjusted for
SHS exposure [17,64,66,74]. Pooling estimates for COPD, chronic
bronchitis/emphysema, chronic bronchitis or emphysema among
never smokers adjusted for passive smoking, the RR was 1.49, 95%
CI: 1.20, 1.85) (data not shown). Significant heterogeneity was
observed among estimates across studies all 59 estimates as well as
among several subgroups including when stratified by control type,
there was also significant heterogeneity among different control
types and when stratified by smoking status (Table 1). When
comparing across pooled estimates, significant heterogeneity was
observed between control types (p=0.009) and between continents
(p,.001). Meta-regression suggested that study design, control type,
smoking status and diagnostic method were predictors of effect size
and contributed to heterogeneity (p,0.05). Continent, gender and
time ofstudydidnot contribute toheterogeneity(Resultsnotshown,
disease specific Galbraith plots included in Figures S1, S2, S3, S4).
Tests for publication bias among all estimates combined were
suggestive of an absence of smaller studies for COPD (Figures S7,
S8, S9, S10). To summarize, the pooled estimates among studies
examining COPD, emphysema and chronic bronchitis suggest that
these factors are associated with a significantly increased risk of lung
cancer. Among studies examining never smokers, significant effects
were not observed, however, were when one outlying study was
removedandamong thosestudiesofneversmokersthat adjustedfor
SHS exposure. Heterogeneity was observed overall, however,
differences across studies can be at least partially explained by
study design, control type, smoking status and diagnostic method.
Pneumonia
Twenty-two studies examined the relationship between pneu-
monia and lung cancer risk while adjusting for smoking (Table S1).
Eleven studies were conducted in North America [17,53,63,
64,65,67,68,69,70,84,89], 7 in Europe [27,52,54,85,86,90,91],
and 4 in East Asia [73,74,79,84]. A significant increase in lung
cancer risk was observed among all studies (overall RR=1.43,
95% CI: 1.22, 1.68). The effect was similar for all studies
combined compared to studies with never smokers only
(RR=1.36, 95% CI: 1.10, 1.69).
The combined effects across all studies separated by participant
smoking status are displayed in forest plot format in Figure 2.
There was no evidence suggestive of publication bias for this
association (Table 1, Funnel plot included in Figure S11). There
was significant heterogeneity across all studies (p,.001, Galbraith
plot included in Figure S5). However, the heterogeneity
diminished when restricting the analysis to never smokers
(p=0.13). Meta-regression suggested that study design, and
continent were predictors of effect size and contributed to
heterogeneity (p,0.05). In summary, a previous diagnosis of
pneumonia across studies was associated with increased lung
cancer risk independent of smoking status, with no evidence of
publication bias.
Tuberculosis
Thirty studies examined the relationship between tuberculosis
and lung cancer while adjusting for smoking (Table S1). Eleven of
the studies were conducted in the North America [17,29,39,
56,62,63,64,65,67,69,70], 15 were conducted in Asia
[73,74,75,76,77,78,79,80,83,84,92,93,94,95,96] and 4 were con-
ducted in Europe [27,85,86,90]. The observed effect across all the
identified studies suggests an increased risk of lung cancer from
tuberculosis (RR=1.76, 95% CI: 1.49, 2.08). The effect was
similar for all studies when compared to only never smokers with
the effect of tuberculosis among never smokers being slightly
elevated (RR=1.90, 95% CI: 1.45, 2.50). The combined effects
across all studies as well as separated by participant smoking status
are displayed in forest plot format in Figure 3. The gender specific
results showed very similar effects for men and women.
Heterogeneity was observed across all tuberculosis studies
combined (p,.001, Galbraith plot included in Figure S6) as well
as among studies that examined populations of smokers (p,.001).
Among never smokers, no heterogeneity was observed (p=0.29).
Publication bias was observed across all studies of tuberculosis
(Funnel plot included in Figure S12), however, not among studies
examining never smokers. In summary, a previous diagnosis of
tuberculosis was associated with increased lung cancer risk across
studies independent of smoking. Heterogeneity was observed
across all studies, however, can be partially attributed to
differences in controls, continent and smoking status and gender
of participants (Table 1).
Discussion
In this meta-analysis, an increased risk of lung cancer was
observed for COPD, emphysema, chronic bronchitis, pneumonia
and tuberculosis when examining the studies that adjusted analyses
for smoking. Of particular interest are the significant effects also
observed among never smokers for pneumonia and tuberculosis.
For chronic bronchitis and emphysema, the combined estimates
were lower among never smokers, indicating that residual
confounding from tobacco may explain some of the effect among
smokers, however, does not appear to fully explain the association.
We estimated the combined effects of previous lung diseases on
lung cancer risk in studies where effects were adjusted for smoking.
Although, the precision of adjustment varied from study to study
as seen in the detailed adjustment column of the study table, in
Previous Lung Disease and Lung Cancer Risk
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17479Figure 1. Pooled estimates of the risk associated with a previous diagnosis of COPD, separated by condition and overall with 95%
confidence intervals. A - study-specific and pooled estimates for chronic bronchitis. B - study-specific and pooled estimates for COPD. C study-
specific and pooled estimates for Emphysema. The estimate labeled Overall – Pooled in panel C represents the combined effects across all three
disease groups. RR relative risk. The pooled RRs were estimated from random effects models. *Studies of never smokers. The study labeled
Ramanakumar, 2006b [70] represents the estimates for one population in study combined among males and females (no combined estimate
originally provided). The studies noted with a b* represent the estimates from a subgroup of never smokers presented in the manuscript which were
not included in the overall estimates.
doi:10.1371/journal.pone.0017479.g001
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direct effects of the diseases adjusted for smoking status. It is
possible that residual confounding of smoking could account for
part of the association observed. Nevertheless, the effects among
never smokers suggest these previous lung diseases such as
pneumonia and tuberculosis have independent effect on lung
cancer risk.
It is difficult to conclude from our results whether it is indeed the
inflammatory sequelae of these diseases that increase lung cancer
risk or whether it is the pathogenesis of the diseases themselves.
While it is likely that the diseases of interest in this investigation act
in different biological causal pathways, if acting independent of
tobacco exposure, however, the inflammatory response is the most
likely common causal link [97].
There are several sources of bias that must be addressed in the
conduct and design of the individual studies as well as in the
synthesis of the studies. The majority of studies reported were case-
control studies in which data concerning previous lung diseases
were abstracted or collected via questionnaire post lung cancer
diagnosis. It is possible that the conditions were early manifesta-
Table 1. Results of the meta-analyses of previous lung diseases overall, by condition, study design/control type and among never
smoking studies.
Previous Lung Disease
No. of
estimates RR
a 95% CI
Heterogeneity
p-value, I
2
Comparison
across groups
p-value
Begg test
p-value
Egger test
p-value
COPD, or CB/E, or Overall 59 1.83 1.60, 2.11 ,.0001, 84.14 0.58 0.002
Emphysema or Cohort 10 1.91 1.34, 2.72 ,.0001, 93.07 0.88 0.80 0.84
Chronic Bronchitis Case-control 49 1.82 1.56, 2.11 ,.0001, 76.00 0.68 0.32
Population based 32 1.80 1.57, 2.04 ,.0001, 54.26 0.009 0.24 0.88
Hospital based 15 2.02 1.32, 3.09 ,.0001, 88.48 0.32 0.25
Never smokers 23 1.22 0.97, 1.53 0.05, 34.88 0.41 0.27
Quantitative diagnosis 10 2.64 2.01, 3.47 0.02, 56.03 0.72 0.41
North America 35 1.80 1.53, 2,12 ,.0001, 83.83 ,.0001 0.73 0.001
Europe 9 1.63 1.11, 2.40 0.012, 81.78 0.55 0.07
Asia 14 2.01 1.43, 2.81 ,.0001, 76.80 0.66 0.26
COPD Overall 16 2.22 1.66, 2.97 ,.0001, 93.55 0.62 0.008
Cohort studies 7 1.86 1.25, 2.77 ,.0001, 94.79 0.55 0.15
Physiological diagnosis 7 2.73 1.94, 3.83 0.008, 65.36 0.88 0.73
Chronic Bronchitis Overall 23 1.52 1.25, 1.84 ,.0001, 69.92 0.79 0.31
Never smokers 12 1.18 0.88, 1.58 0.06, 42.04 0.11 0.13
Emphysema Overall 20 2.04 1.72, 2.41 0.12, 28.52 0.50 0.15
Never smokers 8 1.50 0.96, 2.36 0.30, 6.06 0.27 0.29
Pneumonia Overall 22 1.43 1.22, 1.68 ,.0001, 77.38 0.80 0.51
Population controls 13 1.53 1.22, 1.92 ,.0001, 78.32 0.008 0.63 0.33
Hospital controls 7 1.46 1.12, 1.90 0.006, 67.10 0.55 0.62
Never smokers 8 1.36 1.10, 1.69 0.13, 34.84 0.86 0.42
Serological diagnosis 3 1.74 1.27, 2.38 0.49, 0.00 0.30 0.31
North America 12 1.50 1.22, 1.70 ,.0001, 76.78 0.10 0.50 0.66
Europe 8 1.18 0.89, 1.56 ,.0001, 75.39 1.00 0.32
Asia 4 1.84 1.37, 2.46 0.96, 0.00 1.00 0.87
Tuberculosis Overall 30 1.72 1.46, 2.05 0.001, 51.21 0.01 0.002
Population controls 20 1.53 1.29, 1.81 0.06, 36.00 0.02 0.02 0.02
Hospital controls 8 2.50 1.69, 3.71 0.05, 50.84 0.90 0.53
Never smokers 11 1.90 1.45, 2.50 0.29, 14.48 0.11 0.03
North America 11 1.59 1.17, 2.16 0.14, 32.57 0.37 0.35 0.007
Europe 4 1.44 0.93, 2.23 0.34, 11.57 1.00 0.61
Asia 15 1.96 1.54, 2.50 ,0.001, 63.30 0.01 0.02
Asian never smoking
women
5 2.23 1.38, 3.61 0.16, 39.80 0.22 0.03
CB/E chronic bronchitis and/or emphysema, CI confidence interval, COPD chronic obstructive pulmonary disease, RR relative risk. Where heterogeneity was observed
within groups, p values for heterogeneity across groups were calculated.
aThe pooled RR were estimated from random effects models.
doi:10.1371/journal.pone.0017479.t001
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particularly for emphysema and chronic bronchitis. This is less
probable for pneumonia or tuberculosis, however, tumors may
have been interpreted as lesions from infections prior to cancer
diagnoses.
As an inherited limitation of case-control studies, differential
recall bias may account for part of the association observed.
However, the issues of misclassification and recall bias can be
adequately addressed in the cohort studies included in the
analyses. Also, several of the cohort studies employed quantitative
diagnostic tools such as a measure of forced expiratory volume to
diagnose COPD. This may have reduced the potential for
misclassification bias. Among these studies the effects were
stronger than the results based on the self-reported medical
history, suggesting that recall or misclassification bias do not
explain the association with COPD and may in fact underestimate
the true effect. A previous meta-analysis of exclusively FEV1
among prospective studies with over 5,000 participants calculated
a combined estimate of 2.23 fold (95% CI: 1.93, 8.25) when
comparing the highest quintile of FEV1 to the lowest among the 4
studies included [98].
Several additional sources of potential biases are noteworthy
within the individual studies. The prevalence of previous lung
diseases among controls was often much higher than the baseline
Figure 2. Pooled estimates of the risk associated with a previous diagnosis of pneumonia, separated by smoking status (never
smokers on top, smokers on bottom) and overall. *Studies of never smokers. The pooled RRs were estimates from random effects models. The
study labeled Ramanakumar, 2006b [70] represents the estimates for one population in study combined among males and females (no combined
estimate originally provided). The studies noted with a b* represent the estimates from a subgroup of never smokers presented in the manuscript
which were not included in the overall estimates.
doi:10.1371/journal.pone.0017479.g002
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PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17479Figure 3. Pooled estimates of the risk associated with a previous diagnosis of tuberculosis, separated by smoking status (never
smokers on top, smokers on bottom) and overall. * Studies of never smokers.The pooled RR were estimated from random effects models. The
study by Ger 1993 [76] represents only the estimate using population controls was included. The study labeled Ramanakumar, 2006a [70] represents
the estimates for one population in study using population controls (cancer controls not included), the studies labeled Ramanakumar, 2006b [70]
represents the estimates for the second population in the manuscript study [70] combined among males and females (no combined estimate
originally provided). The study by Chan-Yeung, 2003 [90] represents the estimate combined among males and females (no combined estimate
originally provided). The studies noted with a b* represent the estimates from a subgroup of never smokers presented in the manuscript which were
not included in the overall estimates.
doi:10.1371/journal.pone.0017479.g003
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studies conducted in China, in which 9% [84] and 14% [92]
prevalence as opposed to a point prevalence of pulmonary
tuberculosis of 573 (95% CI 472–631) per 100 000 (1%
prevalence) in a population survey conducted by the China
Tuberculosis Control Collaboration [99] and a lifetime prevalence
of less than 1% in the cohort examined [94]. This suggests the
potential for selection or recall biases in these studies. Several
studies used both direct and next of kin interviews, potentially
leading to differential recall bias as next of kin of the deceased may
have excessively ruminated over questions leading to a higher
likelihood of a positive response among cases. It should also be
noted that COPD may be under-diagnosed in North America
[100].
Reverse causality must also be considered in the cases of
pneumonia and tuberculosis as infections may have been the result
of a weakened immune system due to lung cancer. For these
conditions, ascertainment bias must also be considered as
individuals with tuberculosis or pneumonia may have been more
likely diagnosed with lung cancer due to the use of additional chest
x-rays in the diagnostic work-up often used for the infections. The
possibility of reverse causality was addressed in several studies by
examining the time of infection prior to cancer diagnosis.
Significant increases in risk were consistent in latency analyses
even at greater than 10–20 years since diagnosis of TB [74,92,94].
Combining the latency evidence, although not perfectly consistent
and comparable across studies, suggests that the diseases of interest
are related to lung cancer risk after long exclusion/latency periods.
Among those studies that included latency analyses [27,28,
30,47,64,65,67,68,70,74,89,92], we observed elevated estimates
for .10 and .20 years prior to cancer diagnosis for chronic
bronchitis, tuberculosis and chronic bronchitis, emphysema and
COPD combined. For emphysema and pneumonia elevated
estimates for .10 years were observed (results not shown),
however not for .20 years. It is worth noting that only 20–30%
of studies included, depending on the disease, conducted such
analyses, therefore results should be cautiously interpreted.
Although histology patterns of lung cancer have changed over
time in the last few decades, we did not see any difference in the
effects stratified by study period. (results not shown).
It is also possible that our results, particularly among never
smokers, may have been due to confounding from another source
such as second hand smoke (SHS). SHS has been associated with
increased risk of lung cancer [101] and may be related to previous
lung diseases [102]. The majority of the case-control studies
examining the effects among never smokers have adjusted their
analyses for SHS in an attempt to control for potential
confounding, nevertheless, the possibility of residual confounding
cannot be excluded. Also, occupational exposures may have acted
as confounders in the associations tested as they have been
associated with lung cancer [103], particularly among never
smokers.
We found minimal evidence of publication bias for pneumonia
using standard methodologies. Publication bias may have occurred
in the examination of the previous respiratory conditions of
interest as many studies only reported results for those conditions
that showed a significant association. It appears that for COPD a
surplus of large positive studies or a dearth of smaller negative
studies lead to significant tests. Publication bias was suggested for
tuberculosis. This may be attributable to several of the smaller
Asian studies reporting very large effect estimates. Another
possibility is that Asian studies where small or null effects were
observed not being published in English journals and as such
omitted from this data collection.
The previous lung diseases examined in this meta-analysis as a
group affect a large population of individuals. In the United States,
the conditions have a prevalence of: for emphysema 18.5 per 1000
people, for chronic bronchitis 43.0 per 1000 [9] and tuberculosis
4.8 per 100,00 [10] and although the actual incidence of
pneumonia in the US is unknown there were an estimated 1.4
million hospital discharges from pneumonia infections in 2005
[104]. The positive associations between these conditions and lung
cancer risk are of substantial public health importance due to the
large population exposed.
In conclusion, we observed a consistent positive association
between COPD, emphysema, chronic bronchitis, pneumonia and
tuberculosis and lung cancer risk in this meta-analysis. The
observation of consistent associations when effects were examined
among studies of never smoking cases supports a direct association
between the conditions and lung cancer, reducing the likelihood of
confounding by tobacco exposure. The most likely explanation for
the increased risk associated with these diseases is the inflamma-
tory effects within lung tissue. Previous lung conditions are known
to induce an inflammatory response in the lung [7]. Recent
evidence has suggested that inflammation plays a pivotal role in
the development of lung cancer [97,105,106], particularly among
never smokers. Inflammation may increase the risk of cancer
development as an initiator or promoter through three processes;
increased genetic mutations, anti-apoptotic signaling [107] and
increased angiogenesis [8]. Further investigations into the
potentially causal mechanisms whereby these conditions, promote
lung cancer development are warranted. As such, larger studies or
pooled analyses with the ability for standardized adjustment and
more detailed subgroup analyses would be better suited to address
these issues.
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